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ABSTRACT 
 
Hepcidin is the primary regulatory hormone responsible for lowering the iron content in the blood circulation. Due 
to its biodegradability and low cytotoxicity, hepcidin is considered as an alternative for iron chelators. The 
baculovirus expression system may be suitable for human hepcidin production because the expressed proteins 
generally exhibit proper folding, post-translational modifications, and oligomerization. Using data from two vector 
maps, pFastBac1 and pFastBac HTB, a unique vector was designed encoding human hepcidin-25 as fusion 
recombinant peptide. Expression analysis showed that it was expressed as a peptide with a molecular weight near to 
5 kDa. After purification and TEV treatment, findings revealed that recombinant human hepcidin-25 was functional 
and its effect was dose dependent (P=0.001). It was concluded that baculovirus expression was a suitable 
expression system for production of functional recombinant human hepcidin-25. 
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INTRODUCTION 
 
Hepcidin is a small cysteine-rich antimicrobial 
peptide that functions as main iron regulatory 
hormone (Ganz 2003; 2006). Hepcidin exhibits 
antimicrobial activity against a variety of 
pathogens, including bacteria, viruses, and fungi 
(Krause et al. 2000; Park et al. 2001). It lowers 
iron content in response to iron accumulation, 
hypoxia, and inflammation (Ganz and Nemeth 
2006; Nemeth and Ganz 2006). Hepcidin inhibits 
iron uptake from intestinal cells and iron release 
from reticuloendothelial cells, particularly 
macrophages (Nicolas et al. 2002). It acts by 
binding to ferroportin, the only iron exporting 
channel in mammals (De Domenico et al. 2008) . 
Hepcidin is primarily expressed in liver in the 
 
form of an 84-amino acid precursor, which 
undergoes various post-translational modifications 
to form the mature active hepcidin-25(Pigeon et 
al. 2001). This cysteine-rich peptide contains four 
disulfide bonds. 
There are several methods for the production and 
purification of hepcidin. However, each of these 
methods has limitations. Extraction and 
purification of a natural form of hepcidin from 
urine or plasma resulted in low yield (Ganz 2003; 
2006). A second method is chemical synthesis of 
hepcidin, which requires various refolding 
procedures. In addition, synthetized hepcidin 
molecules have different sizes that may interfere 
with hepcidin function (Rivera et al. 2005). 
Another method for hepcidin production is the 
biological expression system. Incomplete post- 
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translational modification in the bacterial 
expression system (Carvalho et al. 2012), 
differences in glycosylation encountered in the 
yeast expression system (high mannose) 
(Durocher and Butler 2009), and the high cost of 
production when using the mammalian expression 
system prompted to use the baculovirus 
expression system (BES) for human hepcidin 
production. Post-translational modifications such 
as glycosylation, acylation, amidation, 
carboxymethylation, and phosphorylation in BES 
are similar to those found in mammalian cells 
(Patterson et al. 1995). In addition, proteins 
purified using BES is devoid of toxic bacterial 
components, such as lipopolysaccharide (LPS) 
(Hervas-Stubbs et al. 2007). 
This work studied the cloning and expression of 
human hepcidin-25 using BES. Using 
recombinant DNA technology and the cloning 
sites of pFastBac1 and pFastBac HTB vectors, a 
unique construct encoding human hepcidin-25 
was designed. This novel vector encoded 
hepcidin-25 as a fusion protein with a His-tag and 
TEV recognition sites at its N-terminus. 
Expression of the recombinant human hepcidin-25 
was analyzed by SDS-PAGE and Western blot. 
Finally, functional assessment was performed by 
the evaluation of the hepcidin effects on serum 
iron concentration.  To our knowledge, this is the 
first report describing expression of functional 
human hepcidin-25 in the BES. 
 
 
MATERIALS AND METHODS 
 
Designing the coding sequence for recombinant 
human hepcidin  
According to the codon preference observed in 
BES and the cloning site map of pFastBac HTB as 
well as pFastBac1 vectors, a 174 bp coding 
sequence containing His-tag, TEV recognition 
sites and hepcidin-25 sequence was synthesized 
(Shinegene, China). For direct cloning, restriction 
sites of BamHI and EcoRI enzymes were 
introduced respectively at the 5′ and 3′ ends of the 
designed sequence. The synthesized sequence was 
cloned into pFastBac1 vector (Invitrogen, USA). 
Then, the cloning was verified by restriction 
digestion, PCR amplification using specific 
primers, and DNA sequencing using universal 
M13 primers.  
 
Production of recombinant shuttle bacmid and 
recombinant baculovirus 
Recombinant bacmid was produced in Max 
efficiency DH10 Bac competent cells (Invitrogen, 
USA). M13 primers were used for preliminary 
assessment of recombinant bacmid. Orientation of 
the hepcidin coding sequence during homologous 
recombination was analyzed by PCR using M13 
forward and Hepcidin reverse 5′ 
[GAATTCGGTTCTACGTCTTGCAGCACATCC] 3′ 
Primers. Finally, confirmed recombinant bacmid 
was prepared by MidiPrep kit (Invitrogen). 
The insect cell line Sf9 (Pasteur Institute, Iran) 
was used for recombinant baculovirus production. 
Details of the experiments are mentioned 
elsewhere (Yazdani et al. 2011). 
 
Expression analysis of the recombinant human 
hepcidin-25 
For hepcidin expression, Sf9 cells were 
transfected with recombinant baculovirus. 
Preliminary assessment showed that hepcidin 
expression was optimal when cells were incubated 
for 72 h at a multiplicity of infection (MOI) of 10. 
Recombinant hepcidin-25 expression was 
examined by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) 
and Western blot analyses. For Western blot 
analysis, protein samples were loaded on a 15% 
Poly acrylamide gel. The loaded proteins were 
separated by SDS-PAGE and transferred to a 
nitrocellulose membrane and hepcidin expression 
was verified using anti hecidin-25 monoclonal 
antibody (Alpha Diagnostic, USA). A detailed 
description of the protocol used for Western blot 
analysis can be found elsewhere (Yazdani et al. 
2011; 2013) 
 
Hepcidin effect on iron circulation in animal 
model 
Three to four week-old male C57BL/6 mice were 
purchased from the Pasteur Institute of Iran. Mice 
were maintained on a normal iron diet for two 
weeks. Then, mice were treated with a single dose 
of 25 and 50 µg of the recombinant human 
hepcidin-25, intraperitonealy. The treated mice 
were sacrificed 24 h post injection for the 
evaluation of serum iron. Blood was collected 
using cardiac puncture technique and serum iron 
was evaluated by iron assay kit. A detailed 
description of the protocol can be found elsewhere 
(Yazdani et al. 2013). 
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RESULTS AND DISCUSSION 
 
Cloning the coding sequence of recombinant 
human hepcidin 
Based on bioinformatic analysis and the restriction 
maps of pFastBac1 and pFastBac HT B vectors, a 
novel construct encoding human hepcidin-25 was 
design. 
Using GenScript software, the codon adaptation 
index (CAI) was estimated for the designed 
sequence to ensure optimal expression in the BES. 
The CAI was estimated to be 0.72, a reliable index 
for proper expression. Finally, the designed 
sequence was synthesized. PCR and DNA 
sequencing analyses were performed to confirm 
the recombinant pFastBac1-Hepc25 vector. Lane 
1 in Figure 1A shows the 174 bp band 
corresponding to the designed coding sequence. 
For further confirmation, DNA sequencing using 
universal M13 Primers was performed. A 
comparison of DNA sequencing result with the 
sequence found at NCBI confirmed that the 
cloning was successful. 
PCR analysis using M13 primers was used for the 
confirmation of recombinant bacmid. The agarose 
gel electrophoresis pattern showed a band close to 
2,474 bp in length (2,300 bp; bacmid transposed 
with pFastBac1 + 174 bp; hepcidin sequence), 
indicating the correct homologous recombination 
between pFastBac1-Hepc25 and bacterial bacmid 
(Fig. 1B, Lanes 1-4). The orientation of the 
recombinant bacmid was confirmed using M13 
forward and hepcidin reverse primers. The bands 
close to 1700 bp in Lanes 1-3 of Figure 1C 
illustrate the correct orientation of the 
recombinant bacmid. Subsequently, the bacmid 
was used for recombinant baculovirus production 
in Sf9 cells. 
 
 
 
           A 
 
B 
 
 
 
C 
Figure 1 - (A) Agarose (1.5%) gel electrophoresis pattern of the PCR product obtained from 
recombinant pFastBac1-Hepc25 vector (hepcidin specific primers were used for PCR 
amplification). The 174 bp band in Lane 1 illustrates the presence of human hepcidin-25 
in the prepared construct. (B) Agarose (0.8%) gel electrophoresis pattern of the PCR 
product from recombinant bacmid (M13 universal primers were used for PCR 
amplification). The 2474 bp band in Lanes 1–4 illustrates successful homologous 
recombination. (C) Agarose (0.8%) gel electrophoresis pattern of the PCR product from 
recombinant bacmid (M13 forward and hepcidin reverse primers were used for PCR 
amplification). The 1,700 bp band in Lanes 1–3 illustrates the presence of human 
hepcidin-25 in recombinant bacmid. 
 
 
Expression analysis of the recombinant 
hepcidin  
Sf9 cells were used for transient recombinant 
hepcidin-25 production. Hepcidin expression was 
assessed 72 h after baculovirus infection. The 
results of the SDS-PAGE analysis are shown in 
Figure 2. The band close to 5 kDa illustrated the 
recombinant human hepcidin-25 expression (Fig. 2 
Lane 1). Finally, Western blot analysis was 
performed using monoclonal anti-hepcidin-25 
antibody. As shown in Figure 3, Lane 2, the band 
measuring approximately 5 kDa indicated the 
recombinant human hepcidin-25 expression. 
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Figure 2 - Human hepcidin-25 expression in Sf9 cells. 
M: molecular marker (3.4 to 100 kDa), Lane 
1: lysate of Sf9 cells transfected with 
recombinant bacmid. Lane 2: lysate of Sf9 
cells not transfected with recombinant 
bacmid. The peptide band with a molecular 
weight near to 5 kDa indicated expression of 
fusion hepcidin-25. 
 
 
 
Figure 3 - Immunoblott analysis of human hepcidin-25 
in SF-9 cell. M: pre-stained molecular 
marker (10.5 to 175 kDa); lane1: SF-9 cells 
transfected with not recombinant 
baculovirus; lane2: SF-9 cell transfected 
with recombinant bacmid. 
 
 
Functional study of the recombinant human 
hepcidin-25 
The recombinant human hepcidin-25 was purified 
using DEAE column and the His-tag was cleaved 
by tobacco etch virus (TEV) protease (Yazdani et 
al. 2011). Functional assessment was performed 
by the evaluation of the hepcidin effects on serum 
iron concentration (Fig. 4). The obtained data 
indicated that recombinant human hepcidin-25 had 
significantly decreased the iron concentration in 
blood circulation (P = .000). Reduction in the 
serum iron was dose dependent so that 50 µg of 
human hepcidin-25 had higher effect on iron 
concentration (P = 0.001).  
 
 
 
Figure 4 - Hepcidin effects on serum iron concentration. 
The mice received a single dose of 25 and 50 
µg recombinant human hepcidin-25 
separately. Data expressed as the means +/- 
SEM of six mice and P values tested by t test. 
The significant level for P value was P ≤ 
0.05(*means P ≤ 0.05). There was significant 
difference between 25 and 50 µg of the 
recombinant mouse hipcidin-1 (P = 0.001). 
 
 
Antimicrobial peptides are extensively studied in 
the field of innate immunity due to their 
multifunctional roles in physiology (Zasloff 2002). 
Hepcidin, an antimicrobial peptide, plays an 
important role in iron metabolism (Ganz 2003; 
2006). Hepcidin isolated from various species 
exhibit antimicrobial properties against a variety 
of microorganisms (Anderson et al. 2002; Lauth et 
al. 2005). Krause et al. (2000) reported the first 
purification of hepcidin from human plasma and 
called it LEAP-1. Park et al. (2001) named it 
hepcidin due to its antimicrobial properties and 
hepatic origin. 
A previous study has shown that mouse hepcidin-1 
produced in BES is able to lower the serum iron 
levels (Yazdani et al. 2011). Several reports have 
described the cloning and expression of hepcidins 
in various species (Gerardi et al. 2005; Zhang et al. 
2005; Gagliardo et al. 2008; Greenshields et al. 
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2008; Koliaraki, et al. 2008; Lee et al. 2008; 
Srinivasulu et al. 2008; Cai et al. 2012). The 
bacterial expression system is cost- effective, and 
generally the yields are high. However, in 
comparison with the mammalian expression 
system, recombinant proteins purified from 
bacteria generally show incomplete post-
translational modifications (Yazdani et al. 2011). 
Although the yeast expression system presents a 
better alternative for eukaryotic protein 
production, this system often gave rise to high 
mannose glycosylation, a modification that may 
lead to lower half life and efficacy of hepcidin 
(Durocher and Butler 2009). The BES has efficient 
machinery for post-translational modification of 
proteins (mostly like mammalian) (Kost et al. 
2005; Yazdani et al. 2011). Ninety-five percent of 
the recombinant proteins expressed in the BES are 
biologically active (Patterson et al. 1995). Another 
important advantage of this expression system is 
that the entire process of expression and 
purification can be done in an environment devoid 
of cytotoxic bacterial components such as LPS 
(Hervas-Stubbs et al. 2007; Yazdani et al. 2011). 
The BES has been used for the production of 
several antimicrobial peptide (Yazdani et al. 
2011). Studies have shown that the expressed 
proteins contained correct disulfide bonds and 
post-translational modifications including 
glycosylation, phosphorylation and proteolitic 
processing (Greenshields et al. 2008). 
The designed construct for the coding of human 
hepcidin-25 contained His-tag, TEV recognition 
site and coding sequence of human hepcidin 
immediately following ATG codon. The N-
terminal His-tag was introduced to enable nickel-
based purification. Recognition site for TEV was 
introduced so as to enable the removal of His-tag 
from the purified hepcidin-25. This strategy also 
allowed for recombinant hepcidin production with 
a minimum number of extra amino acids at its N-
terminus. Hepcidin coding sequence has only one 
neutral extra amino acid (glycine). Because of its 
neutral nature, the added glycine is not considered 
to significantly affect the peptide folding and 
efficiency (Ladurner and Fersht 1997). 
Based on the present results, an MOI of 10 and  
72 h post infection was identified as suitable 
condition for recombinant hepcidin-25 expression 
(Yazdani et al. 2011). 
Analysis of the designed sequence with ExPASy 
software showed that the future expressed 
hepcidin-25 peptide should have an expected 
molecular weight of approximately 5.8 kDa based 
on its amino acid sequence. The results of SDS-
PAGE analysis showed a band of approximately 5 
kDa that was consistent with expected 
recombinant hepcidin-25 (Fig. 2).  
Previous study has demonstrated that recombinant 
mouse hepcidin-1 significantly decreased 
ferroportin in J774A cell line. But, after infusion 
to the mice peritoneal cavity, the recombinant 
mouse hepcidin-1 mainly displayed a local activity 
on peritoneal macrophages (Yazdani et al. 2013).  
For functional assessment, the mice were given a 
single dose of 25 and 50 µg of the recombinant 
human hepcidin-25, separately. The serum iron 
was assessed 24 h post-injection. Present findings 
showed a reduction in serum iron in both treated 
mice (P=0.000). The results revealed that hepcidin 
effect was dose dependent so that mice treated 
with 50 µg of recombinant human hepcidin-25 
caused a more reduction in serum iron 
concentration (Fig. 4).  
 
 
CONCLUSIONS 
 
This study was the first work that considered 
cloning and functional assessment of hepcidin-25 
using a novel coding sequence in the BES. Results 
suggested that the BES was a suitable expression 
system for the production of small functional 
peptide such as human hepcidin-25.  
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